Fred D. Ledley

Biochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “NIH funding for research underlying new cancer therapies”.

NIH funding for research underlying new cancer therapies

The Lancet Oncology(2020)10.1016/s1470-2045(20)30235-7

N/A

0DataRank · unranked

7 citations

Fred D. Ledley, Ekaterina Galkina Cleary

Foundational research and NIH funding enabling Emergency Use Authorization of remdesivir for COVID-19

medRxiv(2020)10.1101/2020.07.01.20144576

N/A

0DataRank · unranked

11 citations

Matthew J. Jackson, Zoë Folchman-Wagner, Fred D. Ledley, Ekaterina Galkina Cleary

The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccines

medRxiv(2020)10.1101/2020.09.08.20187559

N/A

0DataRank · unranked

2 citations

Ekaterina Galkina Cleary, Matthew J. Jackson, Fred D. Ledley, Anthony E. Kiszewski

NIH funding for vaccine readiness before the COVID-19 pandemic

Vaccine(2021)10.1016/j.vaccine.2021.03.022

N/A

0DataRank · unranked

38 citations

Ekaterina Galkina Cleary, Matthew J. Jackson, Fred D. Ledley, Anthony E. Kiszewski

Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019

JAMA Health Forum(2023)10.1001/jamahealthforum.2023.0511

N/A

0DataRank · unranked

57 citations

Matthew J. Jackson, Edward W. Zhou, Fred D. Ledley, Ekaterina Galkina Cleary

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

JAMA Health Forum(2023)10.1001/jamahealthforum.2023.1921

N/A

0DataRank · unranked

27 citations

Matthew J. Jackson, Fred D. Ledley, Edward Zhou

NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole

PLoS ONE(2023)10.1371/journal.pone.0288447

N/A

0DataRank · unranked

11 citations

Ekaterina Galkina Cleary, Fred D. Ledley

Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis

(2024)10.36687/inetwp219

N/A

0DataRank · unranked

6 citations

Paula G. Chaves da Silva, Debbie Quijada, Fred D. Ledley, Edward Zhou